Video

Dr. Winter Discusses the ZUMA-7 Trial in DLBCL

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial (NCT03391466) in diffuse large B-cell lymphoma (DLBCL).

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial in diffuse large B-cell lymphoma (DLBCL; NCT03391466).

The ZUMA-7 study is evaluating the efficacy of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) compared to standard of care therapy in patients with relapsed/refractory DLBCL. In this phase III randomized, open-label, multicenter study, patients will be randomized to receive axi-cel or standard of care second-line therapy following treatment with first-line rituximab (Rituxan) and anthracycline-based chemotherapy.

Winter says that immunotherapy may be the best strategy for patients with relapsed/refractory DLBCL. This is very exciting for these patients, Winter explains, because there are not many therapeutic choices for this population.

Newsletter

Stay up to date on the most recent and practice-changing oncology data